The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.
作者信息
Kloth Dwight D, Iacovelli Lew, Arbuckle Rebecca, McIntosh Angela C
出版信息
P T. 2010 Apr;35(4):219-29.
Abstract
摘要
相似文献
1
2
Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Tumour Biol. 2017 May;39(5):1010428317705340. doi: 10.1177/1010428317705340.
3
Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
Indian J Cancer. 2017 Dec;54(Supplement):S37-S44. doi: 10.4103/ijc.IJC_532_17.
4
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
JAMA Dermatol. 2017 Sep 1;153(9):906-910. doi: 10.1001/jamadermatol.2017.0903.
5
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
6
The role of EGFR inhibitors in nonsmall cell lung cancer.
Curr Opin Oncol. 2004 Mar;16(2):130-5. doi: 10.1097/00001622-200403000-00008.
7
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Anticancer Drugs. 2006 Aug;17(7):783-95. doi: 10.1097/01.cad.0000217433.48870.37.
8
Anti-epidermal growth factor receptor drugs in cancer therapy.
Expert Opin Investig Drugs. 2002 Jun;11(6):755-68. doi: 10.1517/13543784.11.6.755.
9
Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.
Oncologist. 2018 Sep;23(9):1054-1062. doi: 10.1634/theoncologist.2017-0557. Epub 2018 Apr 27.
10
Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
Oncologist. 2008 Nov;13(11):1201-4. doi: 10.1634/theoncologist.2008-0149. Epub 2008 Nov 6.
引用本文的文献
1
Mediterranean Diet and Agri-Food By-Products: A Possible Sustainable Approach for Breast Cancer Treatment.
Antioxidants (Basel). 2025 Jun 26;14(7):789. doi: 10.3390/antiox14070789.
2
Agri-Food By-Products in Cancer: New Targets and Strategies.
Cancers (Basel). 2022 Nov 10;14(22):5517. doi: 10.3390/cancers14225517.
3
Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan research database.
Support Care Cancer. 2018 Jul;26(7):2369-2377. doi: 10.1007/s00520-018-4091-7. Epub 2018 Feb 8.
本文引用的文献
1
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
J Clin Oncol. 2010 Mar 10;28(8):1351-7. doi: 10.1200/JCO.2008.21.7828. Epub 2010 Feb 8.
2
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Am J Health Syst Pharm. 2009 Dec 1;66(23):2105-12. doi: 10.2146/ajhp090036.
3
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5.
4
Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors.
J Clin Pharmacol. 2009 Oct;49(10):1142-56. doi: 10.1177/0091270009344989. Epub 2009 Sep 1.
5
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Anticancer Drugs. 2009 Nov;20(10):856-66. doi: 10.1097/CAD.0b013e32833034e1.
6
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.
Nat Rev Drug Discov. 2009 Sep;8(9):709-23. doi: 10.1038/nrd2871. Epub 2009 Jul 24.
7
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
J Natl Compr Canc Netw. 2009 May;7 Suppl 1:S5-21; quiz S22-4. doi: 10.6004/jnccn.2009.0074.
8
Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
Jpn J Clin Oncol. 2009 Mar;39(3):137-50. doi: 10.1093/jjco/hyn139. Epub 2008 Dec 16.
9
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.
10
Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
Clin Colorectal Cancer. 2008 May;7(3):202-3. doi: 10.3816/CCC.2008.n.027.
Zotero 插件